Furthermore, the fact that healthy cells are presumably more dependent on the tricarboxylic acid cycle—and therefore IDH3—than cancer cells might contribute to a narrowing of the therapeutic window for HSP90 inhibitors in vivo. Here, HSP90AB1 is linked to cancer.